There were @ ( @ % ) major cardiac adverse events in the bioresorbable scaffold group compared with five ( @ % ) events in the metallic stent group , with the most common adverse events being myocardial infarction ( @ cases -LSB- @ % -RSB- vs two cases -LSB- @ % -RSB- , respectively ) and clinically indicated target-lesion revascularisation ( four cases -LSB- @ % -RSB- vs three cases -LSB- @ % -RSB- , respectively ) .